Loading...

LXEO LEXEO THERAPEUTICS INC US FDA Inspections 8-K Filing

LX T

LX

LEXEO THERAPEUTICS INC

(LXEO)

2025 8-K

Financial Results Update

Director Appointment

Business Highlights

Management Change

Management Changes

Positive Clinical Data

Financial Results Announced

Funding Announcements

Regulatory Update

CFO Transition Announcement

Equity Offerings

Financial Statements

Clinical Data Announcement

Financial Results

Corporate Presentation

CFO Appointment

Management Change

Clinical Data Release

Corporate Update

External Links:

On October 7, 2025, Lexeo Therapeutics, Inc. announced updates regarding an accelerated approval pathway for LX2006 to treat Friedreich ataxia cardiomyopathy, along with positive interim Phase 1/2 clinical data. They will hold a conference call at 8:00 a.m. ET on the same day to discuss these updates.

AI Assistant

LEXEO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.